Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Date:1/4/2012

SAN FRANCISCO, Jan. 4, 2012 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 30th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel on Wednesday, January 11, 2012 at 8:30 a.m. Pacific time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until February 12, 2012.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled seven approved products in the U.S. or Europe for leading biopharmaceutical company partners, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. In addition to the releasable polymer technology, Nektar is the first company to create a permanent small molecule-polymer conjugate with enhanced oral bioavailability and restricted entry into the CNS. Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas. Nektar has an exclusive worldwide license agreement with AstraZeneca for its oral NKTR-118 program to treat opioid-induced constipation and its NKTR-119 program for the treatment of pain without constipation side effects. NKTR-181, a novel mu-opioid analgesic, has completed
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
2. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Therapeutics to Webcast R&D Day on November 12th
5. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
6. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
7. Nektar Announces Retirement of Irwin Lerner from Board of Directors
8. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
10. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
11. Nektar Therapeutics Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... PRINCETON, N.J. , Sept. 17, 2014 /PRNewswire/ ... developing targeted therapeutic devices to address infectious disease, cancer ... Sciences, Inc. (ESI), disclosed today that each company will ... Summit. On September 18 th , ... presentation entitled: "Exosomes: A Multiplexed Platform for Clinical Management." ...
(Date:9/17/2014)... 2014 A biodegradable polymer can ... as bacteria, fungi, and algae into smaller units ... inorganic compounds, carbon dioxide, and humus in a ... and improved costs, biodegradable polymers are proving to ... to conventional polymers. Primary factors that are responsible ...
(Date:9/17/2014)... Hershey, PA & Rockville, MD (PRWEB) September 17, 2014 ... it won a Small Business Innovation Research (SBIR) grant ... allergy immunotherapy. The award will provide ITI with approximately ... , Tree nuts, a leading cause of food allergy, ... leading cause of anaphylaxis behind peanut allergy. Tree nut ...
(Date:9/17/2014)... 2014 Hussey Copper , a leader ... antimicrobial copper, announces Gilmour Academy Ice Arena,s conversion of ... antimicrobial solid touch surface to help protect against bacteria.  ... surface that kills greater than 99.9% of MRSA, E-coli ... , Innovative ...
Breaking Biology Technology:Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 3Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3
... slogans and catchy buzz-phrases to capture the media spotlight as ... equals broadband connectivity (EDEBC) is one of those slogans. ... the test of time. Otherwise, it fades faster than the ... EDEBC is becoming very proven because future economic viability is ...
... advice and $25,000 in cash prizes will be at ... 2007 Northeast Wisconsin Business Plan Contest . , ... existing businesses that are changing direction, in northeastern Wisconsin. ... place reward, entrepreneurs will receive advice about crafting their ...
... - An early-stage company developing diagnostics to test for kidney ... investments to secure federal clearance for its first clinical product. ... of $3.2 million since its inception in 1999, will use ... research and development activities. ,The round was led by Appleton-based ...
Cached Biology Technology:Locations must have connectivity to be viable 2Locations must have connectivity to be viable 3Locations must have connectivity to be viable 4Renovar captures $1.2M for product development 2
(Date:9/17/2014)... professor and his doctoral student have designed a device ... collected from fog and dew., The device could provide ... around the globe., Cheng Luo, professor in the Mechanical ... in the same College of Engineering department, published "Bioinspired ... ACS, (American Chemical Society) Applied Materials & ...
(Date:9/17/2014)... Evolution and Yale University offers compelling support for the ... partially predict the likelihood of being diagnosed with mental ... life. The study analyzed medical records of 1.75 million ... 30 years, and adjusted for almost all other known ... Proceedings of the Royal Society, London B . ...
(Date:9/17/2014)... UTSouthwestern Medical Center have found that the most common ... helps repair the lining of blood vessels. Individuals with ... of this repair, putting them at higher risk for ... one mechanism by which apoE3 promotes a healthy cardiovascular ... said Dr. Philip Shaul , Professor of Pediatrics ...
Breaking Biology News(10 mins):Shorebird's beak inspires UT Arlington research on water collection 2Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Protein variant may boost cardiovascular risk by hindering blood vessel repair 2
... codes of over 40,000 women -- including those ... disease – has uncovered five common genetic variants that ... a paper published online today in the journal Nature, ... association study report that these five genes code for ...
... of the Health Sciences (USU) suggests that it may ... the myriad strains of the HIV virus. HIV is ... stimulate the body to produce cross-reactive antibodies that will ... of truly broad-spectrum neutralizing antibodies may be an achievable ...
... disease typically characterized by the slow but progressive onset ... about five years after diagnosis. However, according to a ... PLoS ONE, a subset of patients with a specific ... complete pulmonary failure and death without a lung transplant. ...
Cached Biology News:First confirmed common genetic risk factors for breast cancer 2Gene expression patterns predict rapid decline in idiopathic pulmonary fibrosis patients 2
Hygromycin resistance gene (hph), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
These are replacement caps for No. CLS6980 5mm PYREX NMR tubes. Proper method to remove caps is to slice them from the tube. Caps come in eight assorted/mixed colors. Packed in bags of 100....
Standard Fluka For microscopy (Hist.) redox indicator...
... The VSN-5 Nutating Mixer is a ... which produces a three dimensional action while ... This high quality unit can be used ... or resuspension of specimens, tissue culture, immunoblots, ...
Biology Products: